

10/021,294

FILE 'CAPLUS' ENTERED AT 15:09:36 ON 15 APR 2005

L1	19549 S CHITOSAN
L2	27952 S CYCLODEXTRIN
L3	340 S L1 AND L2
L4	206883 S CONJUGAT?
L5	11 S L3 AND L4
L6	74841 S OLIGONUCLEOTIDE
L7	428492 S NUCLEOTIDE
L8	713618 S DNA
L9	979555 S L6 OR L7 OR L8
L10	24 S L9 AND L3
L11	30 S L10 OR L5

L11 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:254446 CAPLUS
 DOCUMENT NUMBER: 142:322747
 TITLE: Keratinocyte growth factor-2 formulations
 INVENTOR(S): Gentz, Reiner L.; Chopra, Arvind; Kaushal, Parveen;
 Spitznagel, Thomas; Unsworth, Edward; Khan, Fazal
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: U.S., 43 pp., Cont.-in-part of U.S. Ser. No. 218,444.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6869927	B1	20050322	US 2000-585541	20000602
US 6238888	B1	20010529	US 1998-218444	19981222
NZ 521590	A	20040430	NZ 1998-521590	19981222
US 2002016295	A1	20020207	US 2001-853666	20010514
US 6653284	B2	20031125		
US 2004063639	A1	20040401	US 2003-695957	20031030
PRIORITY APPLN. INFO.:			US 1997-68493P	P 19971222
			US 1998-218444	A2 19981222
			US 1999-137448P	P 19990602
			US 1999-160913P	P 19991022
			NZ 1998-505324	A1 19981222
			US 2001-853666	A3 20010514

AB The invention is directed to liquid and lyophilized forms of keratinocyte growth factor-2 (KGF-2) and derivs. thereof. This invention further relates to the formulation of KGF-2 to promote or accelerate soft tissue growth or regeneration, such as in wound healing, or in treating mucositis or inflammatory bowel disease. For example, a premix formulation containing 3.3 mg/mL KGF-2 Δ33 mutant, 10 mM sodium citrate, 20 mM sodium chloride, 1 mM EDTA, 2% weight/volume glycine, 0.5% weight/volume sucrose, and water (pH 6.2) was prepared and subsequently lyophilized. The formulation retained its in vitro bioactivity for up to 12 mo at storage conditions at or below 25°.

REFERENCE COUNT: 129 THERE ARE 129 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L11 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:140662 CAPLUS
 DOCUMENT NUMBER: 142:214819
 TITLE: Combined nanotechnology and sensor technologies for simultaneous diagnosis and treatment
 INVENTOR(S): Melker, Richard J.; Dennis, Donn Michael
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 345,532.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005037374	A1	20050217	US 2003-744789	20031223
US 2002177232	A1	20021128	US 2002-154201	20020522
US 2004076681	A1	20040422	US 2002-274829	20021021
US 2004081587	A1	20040429	US 2003-722620	20031126
PRIORITY APPLN. INFO.:			US 1999-164250P	P 19991108
			US 2000-708789	B2 20001108
			US 2001-292962P	P 20010523
			US 2002-154201	A2 20020522
			US 2002-274829	A2 20021021
			US 2003-345532	A2 20030116

AB Systems and methods for diagnosing and/or treating conditions, diseases, or disorders. The present invention uses nanoparticle-based assemblies, which comprise a nanoparticle; a surrogate marker; and a means for detecting a specific chemical entity. Such nanoparticle-based assemblies combine nanotechnol. and sensor technol. to provide an efficient and accurate means for diagnosing a condition, disease, or disorder as well as

for focused treatment regimens.

L11 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:57462 CAPLUS
DOCUMENT NUMBER: 142:151492
TITLE: Apparatus, method, and reagents for detection of target substances based on interaction with elliptically polarized light-emitting materials
INVENTOR(S): Matsunami, Yuki; Washisu, Shintaro; Kinoshita, Takatoshi; Kodama, Tomohiro
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 38 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005017094	A2	20050120	JP 2003-181728	20030625
PRIORITY APPLN. INFO.:			JP 2003-181728	20030625

AB The apparatus has (a) a means to irradiate an object with linearly polarized light, (b) a means which can emits elliptically polarized light upon irradiation with the linearly polarized light and change property (e.g. CD spectrum) of the elliptically polarized light upon interaction with a target substance (pathogens, biol. substances, toxic substances, etc.), and (c) a detector of the elliptically polarized light. The reagents used in the apparatus have function of (b) and contain at least a target-capturing site capable of interacting with the target. Thus, a poly(γ -methyl-L-glutamate) film was soaked in 2-aminopyridine solution under a vacuum at 50° for 30 min and the resulting N α -2-pyridylmethyl-L-glutamine- γ -methyl-L-glutamate copolymer film was reacted with CuCl₂.H₂O to give a detection reagent wherein N-2-pyridylmethylpropionamido group formed equimolar complex with Cu²⁺. Poly(4-vinylpyridine) (I) was added to the reagent planed on a quartz glass. Change in 205-nm neg. peak of the CD spectrum showed interaction between the reagent and I and the peak intensity was dependent to amount of I.

L11 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:759628 CAPLUS
DOCUMENT NUMBER: 141:265993
TITLE: Stable and taste masked pharmaceutical dosage forms by using porous apatite grains
INVENTOR(S): Lin, Chang-Yi; Lu, Yunn-Tzer; Liu, Dean-Mo
PATENT ASSIGNEE(S): Nanotrend Ino-Tech Inc., Taiwan
SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 386,546.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004180097	A1	20040916	US 2004-800622	20040316
US 2004180091	A1	20040916	US 2003-386546	20030313
PRIORITY APPLN. INFO.:			US 2003-386546	A2 20030313

AB A stable and taste masked pharmaceutical dosage form includes porous apatite grains and a drug entrapped in pores of the grains, wherein the grains have a size of 0.1-1000 μ m and the pores of the grains have an opening of 0.5-300 nm. A process for preparing the stable and taste masked pharmaceutical dosage form is also disclosed. A powder mixture containing 17.43 g magnesium metaphosphate, 117.03 g monocalcium phosphate, 40.83 g potassium dihydrogen phosphate, 116.2 g calcium hydroxide, and 10 g calcium carbonate, was prepared into a slurry with a mixture solvent of acetone and ethanol as a diluting medium. The total weight of the starting powder is 301.5 g in this study, wherein the Ca/P ratio in the starting powder mixture is 1.55. The slurry was subject to extensive grinding resulting in an average particle size of 95 nm in diameter. The calcium carbonate powder employed is in nanometric scale, having a particle size of 7-10 nm in diameter.

L11 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:488868 CAPLUS
DOCUMENT NUMBER: 142:317019
TITLE: Synthesis of **chitosan** microspheres
containing pendant **cyclodextrin** moieties and
their interaction with biological active molecules
AUTHOR(S): Georgeta, Mocanu; Elie, About-Jaudet; Didier, LeCerf;
Luc, Picton; Adrian, Carpov; Guy, Muller
CORPORATE SOURCE: "Petru Poni" Institute of Macromolecular Chemistry,
Iasi, 6600, Rom.
SOURCE: Current Drug Delivery (2004), 1(3), 227-233
CODEN: CDDUBJ; ISSN: 1567-2018
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new route to obtain **chitosan** derivs. containing
cyclodextrin moieties as pendant groups was developed. The
chitosan microspheres, obtained through crosslinking with
glutaraldehyde of an acetic acid solution of **chitosan**, in an organic
suspension medium, were reacted with chloro-acyl **cyclodextrins**
in organic basic solvents. The acyl **cyclodextrin** moieties are
linked to the **chitosan** microspheres through C-N bonds, with the
elimination of HCl; higher amts. of acyl **cyclodextrin** are linked
to the microspheres with a smaller crosslinking degree. The
chitosan-cyclodextrin conjugates retain higher
amts. of bioactive substances (nalidixic acid, piroxicam) or of
p-nitrophenol (model substance) than their parent **chitosan**
supports, both by ionic forces and by the formation of inclusion complexes
in the **cyclodextrin** inner cavities. After these preliminary
studies, one can appreciate that the **cyclodextrin-**
chitosan conjugates could be used as supports for
chromatog. sepns. or controlled release drug systems.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:252369 CAPLUS
DOCUMENT NUMBER: 140:269531
TITLE: Autologous ghrelin and encoding nucleic acid and
foreign T cell epitope **conjugates** for
vaccination against obesity and excess body fat
increase or loss in human and animal
INVENTOR(S): Boving, Tine Elisabeth Gottschalk; Klysner, Steen
PATENT ASSIGNEE(S): Pharmexa A/s, Den.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024183	A1	20040325	WO 2003-DK592	20030912
WO 2004024183	B1	20040513		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:	DK 2002-1345 A 20020912 US 2002-410164P P 20020912			
AB	Disclosed are novel methods that generally rely on immunization against autologous ghrelin. Immunization is preferably effected by administration of analogs of autologous ghrelin, said analogs being capable of inducing antibody production against the autologous ghrelin polypeptides. Especially preferred as an immunogen is autologous ghrelin, which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against ghrelin and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogs and pharmaceutical formulations, as well as			

nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:1006787 CAPLUS

DOCUMENT NUMBER: 140:47532

TITLE: Quaternary ammonium **cyclodextrins** as pharmaceutical penetration enhancers

INVENTOR(S): Kis, Georg Ludwig; Schoch, Christian; Szejtli, Jozsef

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105867	A1	20031224	WO 2003-EP6192	20030612
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW:				
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
BR 2003011722	A	20050301	BR 2003-11722	20030612
EP 1515729	A1	20050323	EP 2003-740232	20030612
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			EP 2002-13074	A 20020613
			EP 2002-28554	A 20021220
			WO 2003-EP6192	W 20030612

OTHER SOURCE(S): MARPAT 140:47532

AB The use of quaternized ammonium **cyclodextrin** compds. in the preparation of an anti-infective pharmaceutical as preservative and penetration enhancer is disclosed. Thus, a thin-layer film composition contained Mowiol 26-88 100, HPC 40, quaternary ammonium β - **cyclodextrin** derivative 50, and glycerin 10 mg.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:913055 CAPLUS

DOCUMENT NUMBER: 139:399770

TITLE: Medical goods comprising heparin or **chitosan**-based hemocompatible coating

INVENTOR(S): Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato

PATENT ASSIGNEE(S): Hemoteg G.m.b.H., Germany

SOURCE: PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094990	A1	20031120	WO 2003-DE1253	20030415
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10221055	A1	20031127	DE 2002-10221055	20020510

DE 10261986 A1 20040318 DE 2002-10261986 20020510
 EP 1501565 A1 20050202 EP 2003-729829 20030415
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003011446 A 20050315 BR 2003-11446 20030415
 PRIORITY APPLN. INFO.: US 2002-378676P P 20020509
 DE 2002-10221055 A 20020510
 WO 2003-DE1253 W 20030415

AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and **chitosan**. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855982 CAPLUS
 DOCUMENT NUMBER: 139:338810
 TITLE: Hydrogels having enhanced elasticity and mechanical strength properties
 INVENTOR(S): Omidian, Hossein; Qiu, Yong; Yang, Shicheng; Kim, Dukjoon; Park, Haesun; Park, Kinam
 PATENT ASSIGNEE(S): Purdue Research Foundation, USA
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089506	A1	20031030	WO 2003-US12340	20030422
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
US 2003232895	A1	20031218	US 2003-420323	20030422

PRIORITY APPLN. INFO.: US 2002-374388P P 20020422

AB Hydrogels having improved elasticity and mech. strength properties are obtained by subjecting a hydrogel formulation containing a strengthening agent to chemical or phys. crosslinking conditions subsequent to initial gel formation. Superporous hydrogels having improved elasticity and mech. strength properties are similarly obtained whenever the hydrogel formulation is provided with a foaming agent. Interpenetrating networks of polymer chains comprised of primary polymer(s) and strengthening polymer(s) are thereby formed. The primary polymer affords capillary-based water sorption properties while the strengthening polymer imparts significantly enhanced mech. strength and elasticity to the hydrogel or superporous hydrogel. Suitable strengthening agents can be natural or synthetic polymers, polyelectrolytes, or neutral, hydrophilic polymers. Thus, 50% acrylamide solution 500, 1.0% N,N-methylenebisacrylamide solution 100, 10.0% Pluronic F 127 solution 50, glacial acetic acid 50, and 2% aqueous sodium alginate solution 1500 µl were mixed, 50 µl 20% ammonium persulfate solution and 50 µl 20% N,N,N',N'-tetramethylethylenediamine solution was added therein, 30 mg sodium bicarbonate was added therein and reacted,

poured into an 30% aqueous calcium chloride solution, washed, and dried to give a porous hydrogel with good stretching, compression, and bending stress resistance.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:117557 CAPLUS

DOCUMENT NUMBER: 138:158821

TITLE: Inorganic-conditioning agent complexes for the controlled release of medicinals

INVENTOR(S): Royer, Garfield P.; Manda, Joseph A.

PATENT ASSIGNEE(S): Royer Biomedical, Inc., USA

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011214	A2	20030213	WO 2002-US21646	20020226
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-308593P P 20010731

AB This invention relates generally to the production and use of inorg.-conditioning agent complexes for the controlled release of compds. including medicinals. The inorg. used is calcium sulfate and the conditioning agent is calcium stearate. A cement for treating periodontal defects was prepared containing doxycycline pamoate, calcium sulfate, Polysorb 80, and PEG.

L11 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:850328 CAPLUS

DOCUMENT NUMBER: 137:363076

TITLE: Mucin synthesis inhibitors for controlling over production of mucin

INVENTOR(S): Zhou, Yuhong; Levitt, Roy C.; Nicolaides, Nicholas C.; Jones, Steve; McLane, Mike

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U. S. Ser. No. 774,243.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002165244	A1	20021107	US 2001-920287	20010802
US 2001041685	A1	20011115	US 2001-774243	20010131
US 6737427	B2	20040518		
US 2002147216	A1	20021010	US 2001-951906	20010914
JP 2002338493	A2	20021127	JP 2001-316112	20011012
JP 2002338494	A2	20021127	JP 2001-316115	20011012
WO 2003011294	A2	20030213	WO 2002-US21315	20020802
WO 2003011294	A3	20040311		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,			

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1418914 A2 20040519 EP 2002-749809 20020802
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 US 2003236220 A1 20031225 US 2002-290443 20021108
 US 2004254096 A1 20041216 US 2004-838338 20040505
 PRIORITY APPLN. INFO.:
 US 2000-179127P P 20000131
 US 2000-193111P P 20000330
 US 2000-230783P P 20000907
 US 2000-242134P P 20001023
 US 2000-252052P P 20001120
 US 2001-774243 A2 20010131
 US 2001-918711 A2 20010801
 US 2001-920287 A2 20010802
 US 2001-951906 A 20010914
 WO 2002-US21315 W 20020802

OTHER SOURCE(S): MARPAT 137:363076

AB The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compds. in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases. Talniflumate inhibited mucin over production in mice models of asthma.

L11 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:716321 CAPLUS

DOCUMENT NUMBER: 137:246527

TITLE: Multivalent MHC constructs: Immunoanalysis, diagnosis and therapy

INVENTOR(S): Winther, Lars; Petersen, Lars Oestergaard; Buus, Soeren; Schoeller, Joergen; Ruub, Erik; Aamellem, Oeystein

PATENT ASSIGNEE(S): Dako A/S, Den.; Dynal Biotech Asa

SOURCE: PCT.Int. Appl., 304 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072631	A2	20020919	WO 2002-DK169	20020313
WO 2002072631	C1	20021128		
WO 2002072631	A3	20031106		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2440773	AA	20020919	CA 2002-2440773	20020313
EP 1377609	A2	20040107	EP 2002-706685	20020313
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005500257	T2	20050106	JP 2002-571544	20020313
NO 2003004020	A	20031106	NO 2003-4020	20030911
PRIORITY APPLN. INFO.:			DK 2001-435	A 20010314
			DK 2001-436	A 20010314
			DK 2001-441	A 20010314
			US 2001-275447P	P 20010314
			US 2001-275448P	P 20010314
			US 2001-275470P	P 20010314
			WO 2002-DK169	W 20020313

AB The authors disclose MHC mol. constructs (classical and non-classical) **conjugated** to soluble or insol. carriers wherein the affinity and avidity of the constructs exceed that of comparable MHC tetramers. In one example, the construct is comprised of biotinylated HLA-A2 bound to FITC-labeled streptavidin **conjugated** to soluble derivatized dextran. The above construct loaded with MART-1 or influenza virus peptides was shown to effect T-cell activation at a lower concentration than.

Also comprised by the present invention is the sample-mounted use of MHC mols., MHC mol. multimers, and MHC mol. constructs.

L11 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:555628 CAPLUS
DOCUMENT NUMBER: 137:114498
TITLE: Nucleic acid delivery formulations
INVENTOR(S): Barman, Shikha P.; Roy, Krishnendu; Hedley, Mary
Lynne; Wang, Daqing
PATENT ASSIGNEE(S): Zycos Inc., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057424	A2	20020725	WO 2002-US1379	20020117
WO 2002057424	A3	20021003		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2435287	AA	20020725	CA 2002-2435287	20020117
EP 1352072	A2	20031015	EP 2002-713428	20020117
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004521109	T2	20040715	JP 2002-558478	20020117
US 2004147466	A1	20040729	US 2004-466289	20040315
PRIORITY APPLN. INFO.:			US 2001-262219P	P 20010117
			US 2001-270256P	P 20010220
			US 2001-300484P	P 20010622
			WO 2002-US1379	W 20020117

AB The invention is based on the discovery that injectable and nucleic acid-compatible polymeric compns. and formulations can be structurally designed to regulate nucleic acid activity or gene expression in vivo, for example, by controlling the bioavailability of the nucleic acid via modulation of the biodegradability and crosslink d. of the network formed by the components of the formulation. The polymeric network encases the nucleic acid, not only controlling the release of the DNA, but also providing protection from degradation. The invention described herein improves upon prior modes of gene delivery, in that gene expression can be regulated by modulation of a polymeric network formed by combination of at least two water-soluble components capable of reacting with one another. The nucleic acid of interest is incorporated into the network to be released in a sustained manner to achieve level and duration of activity or expression needed.

L11 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:487335 CAPLUS
DOCUMENT NUMBER: 137:68153
TITLE: Novel in-situ forming polymer-based controlled release microcarrier delivery systems
INVENTOR(S): Bhagwatwar, Harshal Prabhakar; Bapat, Varada Ramesh; Paithankar, Mahesh Balkrishna; Yeola, Bhushan Subhash; Gosavi, Arun Shriniwas; Bagool, Manoj Anil; Shetty, Nitin; Shukla, Milind Chintaman; De Souza, Noel John; Khorakiwala, Habil Fakhruddin
PATENT ASSIGNEE(S): India
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049573	A2	20020627	WO 2001-IN219	20011214

PRIORITY APPLN. INFO.:	US 2000-256319P	P	20001218
	WO 2001-IN219	W	20011214

L11 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:368286 CAPLUS
DOCUMENT NUMBER: 136:374550
TITLE: A skin cream composition containing **chitosan
conjugates**
INVENTOR(S): Wadstein, Jan
PATENT ASSIGNEE(S): Wadlund AS, Norway
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.		KIND	DATE	APPLICATION NO.		DATE
WO 2002038123		A1	20020516	WO 2001-NO437		20011101
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FO, GB, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD					
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
NO 310176		B1	20010605	NO 2000-5718		20001113
AU 2002016473		A5	20020521	AU 2002-16473		20011101

EP 1341517 A1 20030910 EP 2001-993455 20011101
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2004043963 A1 20040304 US 2003-416671 20030922
 PRIORITY APPLN. INFO.: NO 2000-5718 A 20001113
 WO 2001-NO437 W 20011101

AB The present invention is related to compns. containing **chitosan conjugated CLA (conjugated linoleic acid)** and a **chitosan conjugated Vitamin A** or a **β -cyclodextrin conjugated vitamin A**. The invention also concerns the preparation of the compns. The compns. according to the invention can be used as topical and cosmetic compns. as well as pharmaceutical compns. for treatment of atypical dermatitis, psoriasis eczema as well as eczema of different origins and solar dermatitis.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:935443 CAPLUS

DOCUMENT NUMBER: 136:58849

TITLE: Compositions and methods to improve the oral absorption of antimicrobial agents

INVENTOR(S): Choi, Seung-Ho; Lee, Jeoung-Soo; Keith, Dennis

PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA; International Health Management Associates, Inc.; University of Utah Research Foundation

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097851	A2	20011227	WO 2001-US19625	20010618
WO 2001097851	A3	20020516		
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
US 6248360	B1	20010619	US 2000-598089	20000621
CA 2413251	AA	20011227	CA 2001-2413251	20010618
EP 1294361	A2	20030326	EP 2001-944619	20010618
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
BR 2001012393	A	20030708	BR 2001-12393	20010618
JP 2003535911	T2	20031202	JP 2002-503335	20010618
NZ 523276	A	20050225	NZ 2001-523276	20010618
US 2003039956	A1	20030227	US 2001-888114	20010622
PRIORITY APPLN. INFO.:			US 2000-598089	A 20000621
			US 2001-829405	A 20010409
			US 2001-283976P	P 20010416
			WO 2001-US19625	W 20010618

AB The present invention provides compns. and methods for increasing absorption of antibacterial agents, particularly third generation cephalosporin antibacterial agents, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, an antimicrobial agent, and a cationic binding agent contained within the biopolymer such that the binding agent is ionically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent. A solution of 44.5 mg calcium chloride in 10 mL water and 1.0 g of ceftriaxone in 10 mL water was added gradually to a solution of 400 mg carrageenan and the dispersion was centrifuged and the supernatant was lyophilized. The resulting composition comprised carrageenan 27.7, ceftriaxone 1, and calcium chloride 3.1%. Plasma concentration of different antimicrobial-biopolymer complexes after oral administration to rats was measured.

L11 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:833060 CAPLUS
 DOCUMENT NUMBER: 135:376741
 TITLE: Stable metal ion-lipid powdered pharmaceutical compositions
 INVENTOR(S): Dellamary, Luis A.; Riess, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E.
 PATENT ASSIGNEE(S): Alliance Pharmaceutical Corp., USA
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085137	A2	20011115	WO 2001-US14824	20010508
WO 2001085137	A3	20020418		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6630169	B1	20031007	US 2000-720536	20001222
CA 2408464	AA	20011115	CA 2001-2408464	20010508
EP 1282405	A2	20030212	EP 2001-933194	20010508
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003533449	T2	20031111	JP 2001-581791	20010508
PRIORITY APPLN. INFO.:			US 2000-568818	A 20000510
			WO 1999-US6855	W 19990331
			WO 2001-US14824	W 20010508

AB Microparticle comps. comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle comps. and methods of treating certain conditions and disease states by administering the microparticle comps. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle comps. of the present invention have superior stability to other microparticle comps. resulting in a microparticle composition with longer shelf life and improved dispersibility. The microparticle comps. of the present invention have a transition temperature (T_m) of at least 20° above the recommended storage temperature (T_{st}) for drug delivery. An aqueous preparation was prepared by mixing two preps., A and B, immediately prior to spray drying. The preparation A was comprised of a fluorocarbon-in-water emulsion in which 26 g perfluorooctyl bromide was dispersed in 33 g water with the aid of 1.30 g of SPC-3 emulsifier (hydrogenated soy phosphatidylcholine). The preparation B contained 0.162 g CaCl₂·2H₂O and 0.162 g budesonide dissolved/suspended in 4 g water. The resulting microparticle of the sample had a PL-budesonide-CaCl₂·2H₂O weight ratio of about 80:10:10. The mean volume aerodynamic particle size of the dry powder was approx. 4.1 μm.

L11 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN .

ACCESSION NUMBER: 2001:822465 CAPLUS
 DOCUMENT NUMBER: 135:357127
 TITLE: Chitosan-containing beverage
 INVENTOR(S): Yamaguchi, Yasuyo
 PATENT ASSIGNEE(S): Kobayashi Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001316271	A2	20011113	JP 2000-132414	20000501
PRIORITY APPLN. INFO.:			JP 2000-132414	20000501

AB Chitosan-containing beverage is prepared from chitosan with the addition of trehalose, glycine, sodium gluconate, etc. to mask the

off-odor of the **chitosan**; and of xanthan gum, pectin, etc., to prevent precipitation. The **chitosan**-containing beverage is useful for prevention and control of gout and hyperuricemia.

L11 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:584837 CAPLUS

DOCUMENT NUMBER: 136:221495

TITLE: The effect of a new skin ointment on skin thickness and elasticity

AUTHOR(S): Thom, E.; Gudmundsen, O.; Wadstein, J.

CORPORATE SOURCE: Parexel Norway AS, Lillestrom, Norway

SOURCE: Journal of Applied Cosmetology (2001), 19(2), 51-57

CODEN: JACOEL; ISSN: 0392-8543

PUBLISHER: International Ediemme

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The present open pilot study was carried out in order to investigate a new patented concept for skin treatment. The new concept is intended for use in treatment of ageing skin. The ointment contains **conjugated** linoleic acid (CLA) and retinyl palmitate (RP). Both ingredients are **conjugated** with the biopolymer **chitosan** in order to improve water solubility, increase skin penetration and inhibit oxidation of the active substances. A number of studies have previously been carried out with **conjugated** retinyl palmitate, where the **conjugation** mostly has been done using β - **cyclodextrin**. We included 20 females in our study and the treatment period was three months. Objective measurements of skin-thickness and elasticity were carried out initially and after three months. Subjective observations and scores were performed by the participants themselves using visual analog scales (VASS) initially and at the end of the study. The results showed a significant improvement in skin quality both with regard to objective as well as in subjective parameters after treatment with the new ointment. In comparison to our previous studies with ointments containing only **conjugated** RP the effects on skin thickness and elasticity were more pronounced with the new formulation showing an average improvement in skin thickness of 51% and in skin elasticity of 27%. The self evaluation scores of the participants were also highly favorable and significant, and all of the participants would like to continue with the ointment after the formal study was closed. The tolerability of the treatment was excellent and all subjects concluded the study according to the protocol.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:564827 CAPLUS

DOCUMENT NUMBER: 135:147436

TITLE: Mucin synthesis inhibitors and their therapeutic use

INVENTOR(S): Zhou, Yuhong; Levitt, Roy C.; Nicolaides, Nicholas C.;

Jones, Steve; McLane, Mike

PATENT ASSIGNEE(S): Magainin Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001054685	A1	20010802	WO 2001-US3078	20010131
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2398642	AA	20010802	CA 2001-2398642	20010131
EP 1255544	A1	20021113	EP 2001-906804	20010131
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004507444	T2	20040311	JP 2001-554669	20010131
PRIORITY APPLN. INFO.:			US 2000-179127P	P 20000131
			US 2000-193111P	P 20000330

US 2000-230783P P 20000907
 US 2000-242134P P 20001023
 US 2000-252052P P 20001120
 WO 2001-US3078 W 20010131

OTHER SOURCE(S): MARPAT 135:147436

AB Methods are provided for modulating mucin synthesis and the therapeutic application of compds. in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD), including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:535393 CAPLUS

DOCUMENT NUMBER: 136:221564

TITLE: Polysaccharides in colon-specific drug delivery

AUTHOR(S): Sinha, V. R.; Kumria, R.

CORPORATE SOURCE: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160 014, India

SOURCE: International Journal of Pharmaceutics (2001), 224(1-2), 19-38

CODEN: IJPHDE; ISSN: 0378-5173

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Natural polysaccharides are now extensively used for the development of solid dosage forms for delivery of drug to the colon. The rationale for the development of a polysaccharide based delivery system for colon is the presence of large amts. of polysaccharidases in the human colon as the colon is inhabited by a large number and variety of bacteria which secrete many enzymes e.g. β -D-glucosidase, β -d-galactosidase, amylase, pectinase, xylanase, β -d-xylosidase, dextranase, etc. Various major approaches utilizing polysaccharides for colon-specific delivery are fermentable coating of the drug core, embedding of the drug in biodegradable matrix, formulation of drug-saccharide **conjugate** (prodrugs). A large number of polysaccharides have already been studied for their potential as colon-specific drug carrier systems, such as **chitosan**, pectin, chondroitin sulfate, **cyclodextrin**, dextrans, guar gum, inulin, amylose and locust bean gum. Recent efforts and approaches exploiting these polysaccharides in colon-specific drug delivery are discussed.

REFERENCE COUNT: 141 THERE ARE 141 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:300486 CAPLUS

DOCUMENT NUMBER: 134:331616

TITLE: Sustained release microspheres based on a carrier protein, a water soluble polymer and complexing agents

INVENTOR(S): Scott, Terrence L.; Brown, Larry R.; Riske, Frank J.; Blizzard, Charles D.; Rashba-Step, Julia

PATENT ASSIGNEE(S): Epic Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028524	A1	20010426	WO 2000-US28200	20001012
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6458387	B1	20021001	US 1999-420361	19991018
EP 1223917	A1	20020724	EP 2000-973477	20001012
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL
 US 2003059474 A1 20030327 US 2002-245776 20020917
 PRIORITY APPLN. INFO.: US 1999-420361 A 19991018
 WO 2000-US28200 W 20001012

AB A microsphere composition for sustained release of therapeutic or diagnostic agents comprises (1) a carrier protein, (2) a water-soluble polymer, (3) a polyanionic polysaccharide as a first complexing agent, and (4) a divalent metal cation (Ca and Mg) as a second complexing agent. The microspheres have a smooth surface that includes a plurality of channel openings that are < 1000 Å in diameter. Various drugs were encapsulated into microspheres. For example, microspheres containing leuprolide acetate were prepared using human serum albumin (HSA), dextran sulfate, polyethylene glycol, and polyvinylpyrrolidone. The microspheres were composed of approx. 10% leuprolide acetate, 50% human serum albumin, 20% dextran sulfate and 20% polyethylene glycol/polyvinylpyrrolidone. Similar particles were prepared which also included zinc sulfate or caprylic acid, both of which retarded the release of protein and peptide from the microspheres. Also, rifampicin-containing HSA microspheres were prepared with HSA incorporation of 74% and rifampicin incorporation into the particles of > 6.8%. The average size of the particles was determined to be 68 nm in diameter.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:136991 CAPLUS
 DOCUMENT NUMBER: 134:198075
 TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
 INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing
 PATENT ASSIGNEE(S): Lipocine, Inc., USA
 SOURCE: PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 12
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012155	A1	20010222	WO 2000-US18807	20000710
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
US 6309663	B1	20011030	US 1999-375636	19990817
CA 2380642	AA	20010222	CA 2000-2380642	20000710
EP 1210063	A1	20020605	EP 2000-947184	20000710
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
JP 2003506476	T2	20030218	JP 2001-516502	20000710
NZ 517659	A	20041224	NZ 2000-517659	20000710
US 2001024658	A1	20010927	US 2000-751968	20001229
US 6458383	B2	20021001		
PRIORITY APPLN. INFO.:			US 1999-375636 A 19990817 WO 2000-US18807 W 20000710	

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a composition containing Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:553206 CAPLUS
DOCUMENT NUMBER: 133:155161
TITLE: Cosmetic composition for protecting the scalp from
free radicals
INVENTOR(S): Herrling, Thomas; Groth, Norbert; Golz-Berner, Karin;
Zastrow, Leonhard
PATENT ASSIGNEE(S): Coty B. V., Neth.
SOURCE: Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1025835	A2	20000809	EP 2000-250030	20000131
EP 1025835	A3	20010801		
EP 1025835	B1	20050323		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
DE 19905127 A1 20000810 DE 1999-19905127 19990201
PRIORITY APPLN. INFO.: DE 1999-19905127 A 19990201
AB The title composition comprises an aqueous dispersion, emulsion, or hydrogel containing
0.5-30 weight% enzymic radical scavenger and 0.1-20 weight% water-soluble or
-dispersible film-forming agent (shellac and/or dextrin). Thus, a radical
scavenger complex comprised phospholipids 7, quebracho extract (containing
proanthocyanidin oligomers and gallic acid) 2, silkworm extract (containing
cecropin, amino acids, and vitamins) 1, acerola (Malpighia punicifolia)
fruit extract 1, vitamin C 0.5, and vitamin A 0.5% in a gel base containing
Carbomer, EtOH, and glycerin. This complex 30.0, α -dextrin 5.0,
 β -dextrin 2.5, γ -dextrin 5.0, preservative 0.5, and H₂O to 100
weight% were combined to produce a scalp spray.

L11 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:157862 CAPLUS
DOCUMENT NUMBER: 132:199065
TITLE: Pharmaceutical preparation containing colloidal
polymer-active substance complexes, in particular for
mucosal administration
INVENTOR(S): Kissel, Thomas; Breitenbach, Armin; Jung, Tobias;
Kamm, Walter
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 40 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19839515	A1	20000309	DE 1998-19839515	19980829

PRIORITY APPLN. INFO.: DE 1998-19839515 19980829
AB Water-soluble, biodegradable polyol esters form colloidal complexes with
pharmacol. active proteins, glycoproteins, peptides, growth factors,
oligonucleotides, and **DNA** constructs and are useful as
carriers for these substances in pharmaceutical dosage forms. Lipophilic
polyol esters are converted into nanoparticles by controlled precipitation and
subsequently loaded with active substances for the same purpose. In both
cases, the resulting active substance-containing colloids show improved
bioavailability, biodistribution, and effectiveness in human or veterinary
applications after mucosal application. These carriers may also be useful
for parenteral administration and transport of active substances to
targeted sites in the body. Thus, a 1:1 M mixture of DL-lactide and
glycolide was melt-grafted onto poly(vinyl alc.) with various degrees of
substitution. The resulting water-soluble ester formed a complex with
tetanus toxoid, the particle size of which depended on ionic strength, pH,
and the presence of emulsifiers.

L11 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:602055 CAPLUS
DOCUMENT NUMBER: 129:312586
TITLE: Purification and characterization of three
thermostable endochitinases of noble Bacillus strain,
MH-1, isolated from chitin-containing compost

AUTHOR(S): Sakai, Kenji; Yokota, Akira; Kurokawa, Hajime;
 Wakayama, Mamoru; Moriguchi, Mitsuki
 CORPORATE SOURCE: Department of Applied Chemistry, Faculty of
 Engineering, Oita University, Oita, 870-1192, Japan
 SOURCE: Applied and Environmental Microbiology (1998), 64(9),
 3397-3402
 CODEN: AEMIDF; ISSN: 0099-2240
 PUBLISHER: American Society for Microbiology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A thermophilic and actinic bacterium strain, MH-1, which produced 3
 different endochitinases in its culture fluid was isolated from
 chitin-containing compost. The microorganism did not grow in any of the usual
 media for actinomycetes but only in colloidal chitin supplemented with yeast
 extract and (2,6-O-dimethyl)- β - **cyclodextrin**. Compost extract
 enhanced its growth. In spite of the formation of branched mycelia, other
 properties of the strain, such as the formation of endospores, the
 presence of meso-diaminopimelic acid in the cell wall, the percent G+C in
DNA (55%), and the partial 16 S ribosomal **DNA** sequence,
 indicated that strain MH-1 should belong to the genus Bacillus. Three
 chitinase isoforms (L, M, and S) were purified to homogeneity and
 characterized from Bacillus sp. strain MH-1. Chitinases L, M, and S had
 different resp. mol. wts. (71, 62, and 53 kDa), pI values (5.3, 4.8, and
 4.7), and N-terminal amino acid sequences. Chitinases L, M, and S showed,
 resp., relatively high temperature optima (75, 65, and 75°) and
 stabilities, and exhibited pH optima in the acidic range (pH 6.5, 5.5, and
 5.5). When reacted with acetylchitoheptaose [(GlcNAc)₆], chitinases L and
 S produced (GlcNAc)₂ at the highest rate, whereas chitinase M produced
 (GlcNAc)₃ at the highest rate. None of the 3 chitinases hydrolyzed
 (GlcNAc)₂. Chitinase L produced (GlcNAc)₂ and (GlcNAc)₃ in greatest
 abundance from 66 and 11% partially acetylated **chitosan**. The
 p-nitrophenol (pNP)-releasing activity of chitinase L was highest toward
 pNP-(GlcNAc)₂, and those of chitinases M and S were highest toward
 pNP-(GlcNAc)₃. All 3 enzymes were inert to pNP-GlcNAc. AgCl, HgCl₂, and
 (GlcNAc)₂ inhibited the activities of all 3 enzymes, whereas MnCl₂ and
 CaCl₂ slightly activated all of the enzymes.
 REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:439388 CAPLUS
 DOCUMENT NUMBER: 129:180116
 TITLE: Synthesis and preliminary studies on a β -
cyclodextrin-coupled **chitosan** as a
 novel adsorbent matrix
 AUTHOR(S): Sreenivasan, K.
 CORPORATE SOURCE: Biomedical Technology Wing, Sree Chitra Tirunal
 Institute for Medical Sciences & Technology,
 Trivandrum, 695012, India
 SOURCE: Journal of Applied Polymer Science (1998), 69(6),
 1051-1055
 CODEN: JAPNAB; ISSN: 0021-8995
 PUBLISHER: John Wiley & Sons, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A novel adsorbent matrix is synthesized by coupling β -
cyclodextrin to **chitosan** using 1,6-hexamethylene
 diisocyanate. The matrix is found insol. in organic as well as acidic or
 alkaline media. The results of our preliminary study on its interaction with
 cholesterol indicates that the modified **chitosan** could be used
 as a novel, reusable sorbent matrix.
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:69602 CAPLUS
 DOCUMENT NUMBER: 120:69602
 TITLE: Preparation and use of polyanionic polymer-based
conjugates targeted to vascular endothelial
 cells
 INVENTOR(S): Thorpe, Philip E.
 PATENT ASSIGNEE(S): University of Texas System, USA; Imperial Cancer
 Research Technology Ltd.
 SOURCE: PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9318793	A1	19930930	WO 1993-US2619	19930322
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, KP, KR, LU, MG, MN, MW, NL, NO, PL, PT, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR				
US 5474765	A	19951212	US 1992-856018	19920323
AU 9338166	A1	19931021	AU 1993-38166	19930322
EP 632728	A1	19950111	EP 1993-907633	19930322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT				
US 5762918	A	19980609	US 1994-307745	19941205
PRIORITY APPLN. INFO.: US 1992-856018 A2 19920323				
WO 1993-US2619 A 19930322				

AB An anionic polymer (e.g. a heparin derivative) is linked to an active agent (especially a steroid), preferably by a selectively hydrolyzable bond, for delivery of the active agent to vascular endothelial cells. The **conjugates** are useful as angiogenesis inhibitors for treatment of e.g. cancer, arthritis, and diabetic blindness. Thus, heparin was condensed with adipic dihydrazide and then with cortisol; the cortisol:heparin mol ratio in the product was 8-9. This **conjugate** was markedly acid labile, suppressed **DNA** synthesis and cell migration in human umbilical vein endothelial cells, retarded or abolished the vascularization of sponges in vivo, and retarded lung tumor growth in mice by 65%. No adverse effects of the **conjugate** were detected, and equivalent treatments with a mixture of heparin and cortisol were significantly less effective in all cases.

L11 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1993:555533 CAPLUS
 DOCUMENT NUMBER: 119:155533
 TITLE: Preparation of monosubstituted tetrahalopyridines and disubstituted trihalopyridines photochemically grafted at the 4-position to other molecules
 INVENTOR(S): Baillarge, Michele; Meziane Cherif, Djalal; Braun, Jacques; Le Goffic, Francois; Francois, Le Goffic
 PATENT ASSIGNEE(S): Vegatec S.a.r.L., Fr.
 SOURCE: Fr. Demande, 25 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2676732	A1	19921127	FR 1991-6200	19910523
FR 2676732	B1	19950224		
PRIORITY APPLN. INFO.: FR 1991-6200 19910523				

AB 4-Azido-2,3,5,6-tetrafluoropyridine (I) and 4-azido-3,5-dichloro-2,6-difluoropyridine are photochem. reacted with a variety of mols., e.g. with polyethylene, polypropylene, latex, polysaccharides, proteins, lipids, nucleic acids, cells, etc. The halopyridine may have a nucleophile at the 2-position. The products are useful as supports in peptide and **oligonucleotide** synthesis, immunoassays, biol., biotechnol. (biocatalysts), etc. (no data). PVDF membranes were immersed in a methanolic solution of I, dried, irradiated 15 min, and washed with MeOH until the wash solution absorption at 254 nm dropped to 0. The membranes were then incubated with a solution of biotin hexamethylene diamine to make membranes for affinity purification of streptavidin.

L11 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1992:241988 CAPLUS
 DOCUMENT NUMBER: 116:241988
 TITLE: Skin cosmetics containing liposomes comprising a light-degradable phosphatidylcholine
 INVENTOR(S): Hashimoto, Akira; Kusumi, Akihiro; Yamaguchi, Kazuo
 PATENT ASSIGNEE(S): Sunstar, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 04029915	A2	19920131	JP 1990-136530	19900524
PRIORITY APPLN. INFO.:			JP 1990-136530	19900524

AB Skin cosmetics contain light-degradable liposomes comprising 2-O₂NC₆H₄CH₂O₂C(CH₂)₁₀CO₂CH₂CH[O₂C(CH₂)₁₀CO₂CH₂C₆H₄NO₂-2]CH₂OP(O)(O-)(O(CH₂)₂NMe₃⁺(I)). 1,10-Decanedicarboxylic acid (II) was refluxed with SOCl₂ for 3 h to give 77% II dichloride, which was treated with 2-nitrobenzyl alc. and Et₃N in THF at room temperature for 11 h to give 15% II mono-2-nitrobenzyl ester. This was stirred with sn-glycero-3-phosphocholine-CdCl₂ complex, DCCD, and 4-dimethylaminopyridine in CHCl₃ at room temperature under dark for 4 days to give 82% I. A CHCl₃ solution containing I was charged in a test tube, dried, mixed with a buffer containing vitamin C at 50° for 10 min, treated with hypersonic waves, and subjected to gel permeation chromatog. to give liposomes, which were irradiated by UV-light for 5 min to release 100% vitamin C. A lotion containing the liposomes (containing vitamin C) was formulated.